Cerevel Therapeutics, co-founded by Pfizer, is set to undertake a reverse merger with Nasdaq-listed Arya II in a deal that will give Cerevel a market cap of $1.3bn.
Cerevel Therapeutics, a US-based developer of treatments for central nervous system disorders backed by pharmaceutical firm Pfizer, yesterday announced its intention to undertake a reverse merger with Arya Sciences Acquisition Corp II.
A group of investors, including Pfizer, are set to invest $320m through a private investment in public equity (Pipe) deal that will be led by Perceptive Advisors.
The Pipe transaction will also be backed by Adage Capital Management, Ally Bridge Group, Boxer Capital, EcoR1 Capital, Federated Hermes Kaufmann…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
